(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051953 A3

(51) International Patent Classification[7]: C07D 487/04, A61K 31/415

(21) International Application Number:
PCT/GB2004/004934

(22) International Filing Date:
24 November 2004 (24.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0327331.5 25 November 2003 (25.11.2003) GB

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **CHENG, Leifeng** [GB/SE]; AstraZeneca R & D Molndal, S-431 83 Molndal (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
28 July 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRROLO-PYRAZINE DERIVATIVES USEFUL AS CB1-MODULATORS



(I)

(57) **Abstract:** The present invention relates to compounds of formula (I); and pharmaceutically acceptable salts thereof, in which R^1 and R^2 independently represent phenyl, thienyl, pyridyl, C_{1-10}alkyl, C_{1-10}alkoxy or C_{3-15}cycloalkyl ; R^3 represents a C_{1-15}alkyl group, C_{3-15}cycloalkyl, a phenylC_{1-4}alkyl group, a heteroaryl group, a heteroarylC_{1-4}alkyl group, or a group $R^4(CH_2)_n$- in which R^4 represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur and n is 0, 1, 2, 3 or 4; X and Y independently represent O or S; m and n independently represent 0 or 1; wherein each of R^1, R^2, R^3 and R^4 is optionally substituted by one, two or three groups represented by Z wherein Z represents a C_{1-6}alkyl group optionally substituted by one or more fluoro, a C_{1-6}alkoxy group optionally substituted by one or more fluoro, hydroxy, halo, trifluoromethylsulphonyl, benzyl, nitro, amino, mono or di C_{1-4}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-6}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl or acetyl and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

WO 2005/051953 A3